A prospective multicenter observational study of cell‐mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients

T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients

(2018) Smaranda Gliga et al.   JOURNAL OF CLINICAL VIROLOGY

Assessment of the T-SPOT.CMV interferon-γ release assay in renal transplant recipients: A single center cohort study

(2018) Dimitrios Chanouzas et al.   PLoS One

The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation

(2018) Camille N. Kotton et al.   TRANSPLANTATION

The performance of T-cell Xtend reagent in increasing blood storage times for interferon gamma release assays

(2017) Junlian Li et al.   JOURNAL OF CLINICAL LABORATORY ANALYSIS

Comparative Analysis of Assays for Detection of Cell-Mediated Immunity Toward Cytomegalovirus andM. tuberculosisin Samples From Deceased Organ Donors

(2014) T. Schmidt et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Preformed Frequencies of Cytomegalovirus (CMV)–Specific Memory T and B Cells Identify Protected CMV-Sensitized Individuals Among Seronegative Kidney Transplant Recipients

(2014) Marc Lúcia et al.   CLINICAL INFECTIOUS DISEASES

CMV: Prevention, Diagnosis and Therapy

(2013) C. N. Kotton   AMERICAN JOURNAL OF TRANSPLANTATION

Pretransplant Immediately Early-1-Specific T Cell Responses Provide Protection for CMV Infection After Kidney Transplantation

(2013) O. Bestard et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Optimization of interferon gamma ELISPOT assay to detect human cytomegalovirus specific T-cell responses in solid organ transplants

(2013) Davide Abate et al.   JOURNAL OF VIROLOGICAL METHODS

Assessment of Cytomegalovirus-Specific Cell-Mediated Immunity for the Prediction of Cytomegalovirus Disease in High-Risk Solid-Organ Transplant Recipients: A Multicenter Cohort Study

(2012) O. Manuel et al.   CLINICAL INFECTIOUS DISEASES

State-of-the-Art Monitoring of Cytomegalovirus-Specific Cell-Mediated Immunity After Organ Transplant: A Primer for the Clinician

(2012) A. Egli et al.   CLINICAL INFECTIOUS DISEASES

The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients

(2010) A. Humar et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Cytomegalovirus Seroprevalence in the United States: The National Health and Nutrition Examination Surveys, 1988–2004

(2010) Sheri Lewis Bate et al.   CLINICAL INFECTIOUS DISEASES

Prolonged Prophylaxis With Valganciclovir Is Cost Effective in Reducing Posttransplant Cytomegalovirus Disease Within the United States

(2010) Emily A. Blumberg et al.   TRANSPLANTATION

Cell-Mediated Immunity to Predict Cytomegalovirus Disease in High-Risk Solid Organ Transplant Recipients

(2009) D. Kumar et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients

(2008) Adrian Egli et al.   Journal of Translational Medicine